Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05109 (
S100A8
)
1,212
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A complex of two S100 EF-hand calcium-binding proteins
S100A8
/A9 induces apoptosis in various cells, especially tumor cells. Using several cell lines, we have shown that
S100A8
/A9-induced cell death is not mediated by the receptor for advanced glycation endproducts (RAGE), a receptor previously demonstrated to engage S100 proteins. Investigation of cell lines either deficient in, or over-expressing components of the death signaling machinery provided insight into the
S100A8
/A9-mediated cell death pathway. Treatment of cells with
S100A8
/A9 caused a rapid decrease in the mitochondrial membrane potential (DeltaPsi(m)) and activated Bak, but did not cause release of apoptosis-inducing factor (AIF), endonuclease G (Endo G) or cytochrome c. However, both Smac/DIABLO and Omi/HtrA2 were selectively released into the cytoplasm concomitantly with a decrease in Drp1 expression, which inhibits mitochondrial fission machinery.
S100A8
/A9 treatment also resulted in decreased expression of the anti-apoptotic proteins Bcl2 and Bcl-X(L), whereas expression of the pro-apoptotic proteins Bax, Bad and
BNIP3
was not altered. Over-expression of Bcl2 partially reversed the cytotoxicity of
S100A8
/A9. Together, these data indicate that
S100A8
/A9-induced cell death involves Bak, selective release of Smac/DIABLO and Omi/HtrA2 from mitochondria, and modulation of the balance between pro- and anti-apoptotic proteins.
...
PMID:S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. 1806 Aug 80
The complex formed by two members of the S100 calcium-binding protein family,
S100A8
/A9, exerts apoptosis-inducing activity in various cells of different origins. Here, we present evidence that the underlying molecular mechanisms involve both programmed cell death I (PCD I, apoptosis) and PCD II (autophagy)-like death. Treatment of cells with
S100A8
/A9 caused the increase of Beclin-1 expression as well as Atg12-Atg5 formation.
S100A8
/A9-induced cell death was partially inhibited by the specific PI3-kinase class III inhibitor, 3-methyladenine (3-MA), and by the vacuole H(+)-ATPase inhibitor, bafilomycin-A1 (Baf-A1).
S100A8
/A9 provoked the translocation of
BNIP3
, a BH3 only pro-apoptotic Bcl2 family member, to mitochondria. Consistent with this finding, DeltaTM-
BNIP3
overexpression partially inhibited
S100A8
/A9-induced cell death, decreased reactive oxygen species (ROS) generation, and partially protected against the decrease in mitochondrial transmembrane potential in
S100A8
/A9-treated cells. In addition, either DeltaTM-
BNIP3
overexpression or N-acetyl-L-cysteine co-treatment decreased lysosomal activation in cells treated with
S100A8
/A9. Our data indicate that
S100A8
/A9-promoted cell death occurs through the cross-talk of mitochondria and lysosomes via ROS and the process involves
BNIP3
.
...
PMID:S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. 1993 72